Channel NewsAsia |
FDA Approves IDH2 Inhibitor for AML
MedPage Today The FDA today approved the targeted agent enasidenib (Idhifa) for adults with relapsed or refractory acute myeloid leukemia (AML) associated with isocitrate dehydrogenase-2 (IDH2) mutations. At the same time, the agency approved the RealTime IDH2 ... FDA approves leukemia treatment developed by Celgene, Agios A small biotech behind a groundbreaking approach to tackling cancer just got its first drug approved Cambridge biotech Agios wins approval for its leukemia drug |
from Health - Google News http://ift.tt/2wiRYae
EmoticonEmoticon